Agno Pharma Acquires Actylis’s CDMO Manufacturing Asset, the Legacy Cascade Chemistry Business based in Eugene, Oregon, Strengthening Agno’s US cGMP API Development and Manufacturing Capabilities

BETHLEHEM, Pa.--(BUSINESS WIRE)--Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.

With over 20 years history, the Eugene site brings a strong legacy in small-molecule API development and manufacturing, anchored by a 16,000 square-foot R&D lab facility as well as a newly constructed 30,000 square-foot manufacturing facility, equipped with state-of-the-art GMP infrastructure supporting early-phase to late-phase clinical API production. Under Actylis, the Eugene site received significant investment to expand and upgrade its GMP manufacturing operations, and represents a robust platform well positioned for future growth.

“We would like to thank Actylis for its investments and stewardship of the Eugene site, and we are extremely excited to welcome the Eugene team into the Agno Pharma platform,” said James Chen, PhD, Chief Executive Officer of Agno Pharma. “This acquisition is a transformative step forward in building a differentiated development and manufacturing hub. The Eugene site brings technical depth in early-phase API development and its high-quality GMP infrastructure will be a powerful driver of new business as we support innovative biotech and pharmaceutical partners developing novel chemical entities.”

Today, Agno Pharma already serves a global client-base including blue-chip pharmaceutical and biotech companies, supplying critical GMP intermediates and APIs, drug product and drug implant formulation services, as well as analytical services from preclinical through commercial phases. The acquisition of the Eugene asset meaningfully expands Agno’s manufacturing footprint and reinforces its commitment to serve its customers with onshore pharmaceutical manufacturing in the U.S.

Following the transaction, Agno plans to execute a disciplined and seamless integration, maintaining uninterrupted service for existing customers and accelerating investment in the site to enhance capabilities and drive long-term growth.

About Agno Pharma

Founded in 2004 and headquartered in Bethlehem, PA, Agno Pharma is an end-to-end contract development and manufacturing organization (CDMO), serving blue-chip pharmaceutical and biotech companies worldwide. Agno provides comprehensive solutions across the entire drug lifecycle from preclinical development through commercial manufacturing. With FDA-inspected, cGMP-compliant facilities and a multidisciplinary team of scientific and technical experts, Agno is committed to delivering high-quality, scalable, and integrated development and manufacturing solutions that help advance therapeutic programs from concept to market.

About Actylis

Actylis is a global solutions provider with over 75 years of experience, specializing in streamlining the management of critical ingredients and raw materials for its customers. With business operations in 10 countries, Actylis manufactures and supplies more than 3,000 raw materials and critical ingredients that are used in the pharmaceutical, nutrition, cosmetics, agricultural, and specialty chemical industries. The company offers customized sourcing solutions ensuring a reliable, agile and secure supply network for its customers by reducing complexity and mitigating risk. Over the last five years, Actylis has expanded its manufacturing, R&D, and portfolio through a combination of organic investment and strategic M&A, transforming the company into a diversified platform of offerings. Actylis’ global operations, including a significant presence on the ground in North America, Europe, India and China, enable the company’s deep worldwide sourcing, quality and regulatory capabilities. Actylis is well positioned to drive new innovative sourcing solutions, ensure quality and customize products to meet customers’ specific raw material and critical ingredient needs. For more information visit Actylis.com.

Wombat Capital served as financial advisor, UB Greensfelder LLP as legal advisor, and Grant Thornton provided accounting, audit, and tax advisory services to Actylis in connection with the transaction.